
🧬 Mark Kotter - bit.bio - Part 1 | Childhood Experiences in Different Countries | Overcoming Dyslexia & Developing Math Skills | Pivoting His Career to Science and Medicine | Facilitating Curiosity Via Research & Lab Experiences
Part 1 of 4. My guest for this week’s episode is Mark Kotter, neurosurgeon, stem cell biologist, and CEO and founder of bit.bio. Bit.bio is an award-winning human synthetic biology company providing human cells for research, drug discovery, and cell therapy. Bit.bio applies a patented safe harbor gene targeting approach to inducibly express transcription factor combinations that reprogram human-induced pluripotent stem cells into highly defined and mature human cell types. Bit.bio spun out of the University of Cambridge in 2016 and has since raised approximately $200 million from Arch Ventures, Foresight Capital, Milky Way, Charles River Laboratories, National Resilience, Tencent, and Pulau Capital, among others.
The Biotech Startups Podcast · Excedr
Audio is streamed directly from the publisher (media.fame.so) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
My guest for this week’s episode is Mark Kotter, neurosurgeon, stem cell biologist, and CEO and founder of bit.bio. Bit.bio is an award-winning human synthetic biology company providing human cells for research, drug discovery, and cell therapy. Bit.bio applies a patented safe harbor gene targeting approach to inducibly express transcription factor combinations that reprogram human-induced pluripotent stem cells into highly defined and mature human cell types. Bit.bio spun out of the University of Cambridge in 2016 and has since raised approximately $200 million from Arch Ventures, Foresight Capital, Milky Way, Charles River Laboratories, National Resilience, Tencent, and Pulau Capital, among others.
- Mark's upbringing as a curious child in Canada and his exposure to a broad range of cultures and perspectives
- His experiences growing up with dyslexia and how it led him to focus on science and mathematics at an early age
- His experience as a researcher and PhD student at Cambridge, where he transitioned from medicine to synthetic biology and stem cell research
- And much more!
Timestamps:
Social & Website